Literature DB >> 30389174

Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.

Prisca M J Theunissen1, Maaike de Bie1, David van Zessen2, Valerie de Haas3, Andrew P Stubbs4, Vincent H J van der Velden5.   

Abstract

Antigen receptor gene rearrangements are frequently applied as molecular targets for detection of minimal residual disease (MRD) in B-cell precursor acute lymphoblastic leukemia patients. Since such targets may be lost at relapse, appropriate selection of antigen receptor genes as MRD-PCR target is critical. Recently, next-generation sequencing (NGS) - much more sensitive and quantitative than classical PCR-heteroduplex approaches - has been introduced for identification of MRD-PCR targets. We evaluated 42 paired diagnosis-relapse samples by NGS (IGH, IGK, TRG, TRD, and TRB) to evaluate clonal evolution patterns and to design an algorithm for selection of antigen receptor gene rearrangements most likely to remain stable at relapse. Overall, only 393 out of 1446 (27%) clonal rearrangements were stable between diagnosis and relapse. If only index clones with a frequency >5% at diagnosis were taken into account, this number increased to 65%; including only index clones with an absolute read count >10,000, indicating truly major clones, further increased the stability to 84%. Over 90% of index clones at relapse were also present as index clone at diagnosis. Our data provide detailed information about the stability of antigen receptor gene rearrangements, based on which we propose an algorithm for selecting stable MRD-PCR targets, successful in >97% of patients.
Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  B-cell precursor ALL; Immunoglobulin and T-cell receptor gene rearrangements; Minimal residual disease; Next generation sequencing; Relapse

Mesh:

Substances:

Year:  2018        PMID: 30389174     DOI: 10.1016/j.leukres.2018.10.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.

Authors:  Paraskevi Diamanti; Charlotte V Cox; Benjamin C Ede; Robert A Uger; John P Moppett; Allison Blair
Journal:  Blood Adv       Date:  2021-09-28

Review 2.  Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.

Authors:  In-Suk Kim
Journal:  Blood Res       Date:  2020-07-31

Review 3.  Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.

Authors:  Ricardo Sánchez; Rosa Ayala; Joaquín Martínez-López
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

Review 4.  Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

Authors:  Kyaw Hein; Nicholas Short; Elias Jabbour; Musa Yilmaz
Journal:  Blood Lymphat Cancer       Date:  2022-03-19

Review 5.  Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.

Authors:  Xinyue Deng; Meilan Zhang; Jianfeng Zhou; Min Xiao
Journal:  Exp Hematol Oncol       Date:  2022-09-03

Review 6.  Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells.

Authors:  Michaela Kotrova; Nikos Darzentas; Christiane Pott; Claudia D Baldus; Monika Brüggemann
Journal:  Genes (Basel)       Date:  2021-06-27       Impact factor: 4.096

7.  [A correlation study between the minimal residual disease detection using multiparameter flow cytometry and prognosis of childhood acute B lymphoblastic leukemia].

Authors:  J Feng; X J Chen; X M Liu; Y Zou; Y Guo; W Y Yang; Y M Chen; L Zhang; S C Wang; M Ruan; F Liu; T F Liu; B Q Qi; X F Zhu; H J Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.